$ASEI (American Science & Engineering Inc.)

$ASEI {{ '2016-01-11T22:31:03+0000' | timeago}} • Announcement

Threat and contraband detection solutions provider $ASEI said it named Diane Basile as SVP, CFO, and Treasurer of the company, effective today. Basile will report to Chuck Dougherty, $ASEI President and CEO. She succeeds Kenneth Galaznik. Galaznik will continue to serve as a SVP of the company and will work in an advisory capacity.

$PLXS {{ '2018-01-17T21:53:35+0000' | timeago}} • Announcement

$PLXS said it expects 2Q18 revenues to be in the range of $670MM to $710MM.  Excluding any potential effect of the tax reform, second quarter GAAP EPS is forecasted in the $0.68-$0.78 range, on gross margins of 4.3-4.7%. Cash outflows are estimated to be between $30MM and $50MM. In fiscal 2018, free cash flow is anticipated to exceed $100MM.

$PLXS {{ '2018-01-17T21:42:46+0000' | timeago}} • Announcement

$PLXS, a tech firm in the electronics industry, slipped into the negative territory in 1Q18 reporting a loss of $2.93 per share, compared to profit $0.82 per share a year earlier. The results were impacted by an expense related to the US tax reform. On a non-GAAP basis, Plexus reported earnings of $0.75 per share. Revenues advanced 7% to $677MM.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$HOLX {{ '2018-01-16T13:05:50+0000' | timeago}} • Announcement

$HOLX said its CE-marked Aptima HIV-1 Quant Dx assay has been awarded World Health Organization (WHO) prequalification for in vitro diagnostic. The Aptima HIV-1 Quant Dx assay is the first HIV-1 viral load assay with a dual claim for both diagnosis and treatment monitoring.

$HOLX {{ '2018-01-11T21:23:15+0000' | timeago}} • Announcement

Medical technology company $HOLX has elected Namal Nawana to its board of directors, effective immediately. Nawana was formerly the CEO of Alere, Inc. Prior to that, he served Johnson & Johnson in various leadership roles, including Worldwide President of DePuy Synthes Spine.

$LLL {{ '2018-01-09T19:22:10+0000' | timeago}} • Announcement

$LLL appointed retired U.S. Army Lt. Gen. Patrick J. "Pat" O'Reilly to the newly created role of corporate Vice President of Engineering, effective immediately. In this new position, O'Reilly will report to the company's Chief Technology Officer, Paul DeLia.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$LLL {{ '2018-01-08T16:06:44+0000' | timeago}} • Announcement

$LLL, which provides electronic systems to multiple industries, appointed Sean Stackley as Corporate VP for Strategic Advanced Programs and Technology. He will report directly to Heidi Wood, SVP for Corporate Strategy and Technology. Previously, Stackley served as Assistant Secretary of the Navy and an advisor to the Under Secretary of Defense.

$HOLX {{ '2018-01-08T13:10:32+0000' | timeago}} • Announcement

Medical technology company $HOLX said it is currently looking for net revenues of about $791MM for the first quarter of 2018, higher than $775MM-$790MM the company had estimated earlier. The latest guidance represents an 8% YoY growth, reflecting the effect of divestiture of Hologic’s blood screening business and acquisition of Cynosure.

$HOLX {{ '2018-01-03T13:10:03+0000' | timeago}} • Announcement

$HOLX said the MyoSure MANUAL device, which was designed to simplify tissue removal procedures regardless of setting, has received CE mark in Europe. The MyoSure MANUAL device joins the MyoSure suite of gynecologic surgical products that offer simple and effective solutions to resect and remove tissue.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$CACI {{ '2017-12-21T17:45:08+0000' | timeago}} • Announcement

$CACI received a blanket purchase agreement (BPA) to provide support services to the Drug Enforcement Administration (DEA). This BPA represents continuing work for CACI in its Business Systems market area.

$NOC {{ '2017-12-21T14:52:32+0000' | timeago}} • Announcement

$NOC appointed Yolanda Murphy as VP of communications for its Technology Services sector, succeeding Alleace Gibbs, who will now serve as VP of communications for its Mission Systems sector, effective Jan. 1, 2018. Murphy will become a new member of Northrop Grumman's Communications Council. Gibbs will remain a member of that leadership group.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$NSP {{ '2017-12-18T14:06:16+0000' | timeago}} • Announcement

$NSP's BoD appointed Randall Mehl as a new independent director. Mehl has been appointed as a Class 3 director with a term expiring at its annual meeting of the stockholders in 2019. Mehl currently serves on the boards of $ICFI and $KFRC and is the President of Stewardship Capital Advisors LLC.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$LLL {{ '2017-12-14T21:07:02+0000' | timeago}} • Announcement

Diversified technology company $LLL has named John Feren VP of Business Development and Marketing, Commercial Aviation. He will be reporting to SVP Todd Gautier. Previously, Feren had served Aviation Capital Group as EVP and Head of Global Strategy & Development. Prior to that, he held various key roles in Boeing Company.

$AGN {{ '2017-12-12T19:58:45+0000' | timeago}} • Announcement

$AGN gets FDA clearance for the CoolSculpting, a treatment to improve the appearance of lax tissue in double chin. Allergan got this CoolSculpting technology by acquiring Zeltiq Aesthetics in Feb. 2017 for $2.4Bil. Allergan added that in an 18-week study, 77% of patients showed improved appearance in their lax tissue.

Recent Transcripts

TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
CNCE (Concert Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 1:30pm
HOLX (Hologic Inc.)
Wednesday, November 8 2017 - 9:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
BAH (Booz Allen Hamilton Holding Corporation)
Monday, November 6 2017 - 1:00pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
KTOS (Kratos Defense & Security Solutions, Inc.)
Thursday, November 2 2017 - 9:00pm
UEIC (Universal Electronics Inc.)
Thursday, November 2 2017 - 8:30pm
ICFI (ICF International Inc.)
Thursday, November 2 2017 - 8:30pm
SMTX (SMTC Corporation)
Thursday, November 2 2017 - 8:30pm
CACI (CACI International Inc.)
Thursday, November 2 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
ITGR (Integer Holdings Corporation)
Thursday, October 26 2017 - 9:00pm
LLL (L-3 Communications Holdings Inc.)
Thursday, October 26 2017 - 3:00pm
PLXS (Plexus Corp.)
Thursday, October 26 2017 - 12:30pm
NOC (Northrop Grumman Corporation)
Wednesday, October 25 2017 - 4:00pm
CACI (CACI International Inc.)
Thursday, August 17 2017 - 12:30pm
PTLA (Portola Pharmaceuticals, Inc.)
Wednesday, August 9 2017 - 8:30pm

AlphaGraphics you may like